질 항진균제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for vaginal antifungals. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global vaginal antifungals market from 2025 to 2032.

Key Insights:

• Vaginal Antifungals Market Size (2025E): USD 1,133.60 Million
• Projected Market Value (2032F): USD 1,375.30 Million
• Global Market Growth Rate (CAGR 2025 to 2032): 2.8%

Vaginal Antifungals Market - Report Scope:

Vaginal antifungals are essential medications used to treat fungal infections such as vulvovaginal candidiasis, commonly caused by Candida species. These treatments are available in various forms, including creams, suppositories, tablets, and ointments, catering to both prescription-based and over-the-counter (OTC) usage. The market serves gynecology clinics, retail pharmacies, online platforms, and hospitals. Growing awareness about women's intimate health, rising incidences of vaginal infections, and increased accessibility to antifungal treatments contribute significantly to market development.

Market Growth Drivers:

The global vaginal antifungals market is driven by a number of key factors. A surge in lifestyle-related infections, increased antibiotic use, and a rise in diabetic populations have all contributed to higher rates of recurrent fungal infections. Moreover, consumer preference for quick, effective, and discreet treatment options has led to a spike in demand for OTC antifungal products. Product innovation, such as extended-release formulations and combination therapies, enhances convenience and treatment adherence. Campaigns promoting menstrual and vaginal health awareness further boost product visibility and adoption, especially in urban and semi-urban regions.

Market Restraints:

Despite encouraging growth prospects, the vaginal antifungals market encounters challenges including limited awareness in low-income regions, social stigma around discussing vaginal health, and the growing concern of antifungal resistance. Misdiagnosis and self-medication can lead to improper treatment, reducing overall efficacy and consumer trust. Regulatory constraints, especially for newer formulations and combination products, can hinder market entry and delay approvals. In some regions, cultural barriers and lack of education contribute to underdiagnosis and undertreatment of fungal infections.

Market Opportunities:

Opportunities in the vaginal antifungals market stem from increasing demand for personalized and natural treatment options. The rising trend of plant-based and probiotic-infused formulations provides scope for innovation. Expansion of telehealth services allows discreet consultations, expanding treatment access. Partnerships between pharmaceutical companies and women's wellness platforms enable broader market penetration. Growing e-commerce infrastructure, particularly in Asia Pacific and Latin America, is opening up new revenue streams for manufacturers of OTC antifungal solutions. Enhanced diagnostic tools and self-test kits also create cross-selling opportunities for antifungal therapies.

Key Questions Answered in the Report:

• What are the primary drivers accelerating the growth of the vaginal antifungals market worldwide?
• Which dosage forms and formulations are most preferred across different consumer segments?
• How are changing consumer behaviors and e-commerce trends impacting the vaginal antifungals landscape?
• Who are the leading players in the market, and what strategies are being adopted to sustain growth?
• What are the emerging opportunities and long-term outlook for the vaginal antifungals market?

Competitive Intelligence and Business Strategy:

Prominent players in the vaginal antifungals market, including Lupin Limited, Pfizer Inc., and Bausch Health Companies Inc, are focusing on developing user-centric products that combine efficacy with comfort. Companies are increasingly investing in R&D to introduce extended-release suppositories, multi-symptom relief creams, and probiotic-integrated products. Strategic collaborations with gynecological associations and wellness influencers help increase awareness and product credibility. In addition, expanding retail presence and digital marketing strategies are enabling brands to reach younger, digitally-savvy consumers seeking accessible and private treatment options.

Key Companies Profiled:

• Pfizer Inc.
• Bausch Health Companies Inc
• ANI Pharmaceuticals, Inc.
• Hikma Pharmaceuticals Plc
• Lupin Limited
• Mycovia Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Unique Pharmaceuticals
• PEPTONIC medical AB
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories
• SCYNEXIS, Inc.
• Basilea Pharmaceutica Ltd.
• Astellas Pharma Inc.
• Grupo Ferrer Internacional, S.A.
• Pacgen Life Science Corporation
• NovaDigm Therapeutics, Inc.
• Cidara Therapeutics, Inc.
• Amplyx Pharmaceuticals Inc.

Vaginal Antifungals Industry Research Segments

By Drug:

• Fluconazole
• Nystatin
• Flucytosine
• Clotrimazole
• Ketoconazole
• Terbinafine
• Others

By Route of Administration:

• Oral
• Topical

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Key Innovation / Development Trends

4. Key Success Factors

• 4.1. Promotional Strategies, By Key Manufacturers
• 4.2. Key Regulations
• 4.3. Reimbursement Scenario
• 4.4. Pipeline Analysis
• 4.5. Value Chain Analysis
• 4.6. PESTEL Analysis
• 4.7. Porter's Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure Outlook
  • 5.1.3. Global Antifungal Drugs Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Impact of the COVID-19 Pandemic
  • 5.2.2. Increasing Product Launch Activities
  • 5.2.3. Prevalence of Vaginal Fungal Infections in HRT Patients
  • 5.2.4. High Rates of Vulvovaginal Candidiasis
  • 5.2.5. Impact on Quality-of-Life
  • 5.2.6. Increasing Number of People with Predisposing Conditions Such as Diabetes Treated with SGLT2 Inhibitors
  • 5.2.7. Growing Problems of Azole Resistance
  • 5.2.8. Toxicity of Antifungal Drugs
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Drug
  • 6.1.2. By Route of Administration
  • 6.1.3. By Distribution Channel
  • 6.1.4. By Country
• 6.2. 2021 Market Scenario

7. Global Vaginal Antifungals Market Demand (in Value or Size in US$ Mn) Analysis 2019-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2024
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2025-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Vaginal Antifungals Market Analysis 2019-2032, By Drug

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2019-2024
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2025-2032
  • 8.3.1. Fluconazole
  • 8.3.2. Nystatin
  • 8.3.3. Flucytosine
  • 8.3.4. Clotrimazole
  • 8.3.5. Ketoconazole
  • 8.3.6. Terbinafine
  • 8.3.7. Others
• 8.4. Market Attractiveness Analysis By Drug

9. Global Vaginal Antifungals Market Analysis 2019-2032, By Route of Administration

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2024
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2025-2032
  • 9.3.1. Oral
  • 9.3.2. Topical
• 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Vaginal Antifungals Market Analysis 2019-2032, By Distribution Channel

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2024
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2025-2032
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Vaginal Antifungals Market Analysis 2019-2032, By Region

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2024
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2025-2032
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. East Asia
  • 11.3.5. South Asia
  • 11.3.6. Oceania
  • 11.3.7. Middle East and Africa
• 11.4. Market Attractiveness Analysis By Region

12. North America Vaginal Antifungals Market Analysis 2019-2032

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 12.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 12.3.1. By Country
    • 12.3.1.1. U.S.
    • 12.3.1.2. Canada
  • 12.3.2. By Drug
  • 12.3.3. By Route of Administration
  • 12.3.4. By Distribution Channel
• 12.4. Market Attractiveness Analysis
  • 12.4.1. By Country
  • 12.4.2. By Drug
  • 12.4.3. By Route of Administration
  • 12.4.4. By Distribution Channel
• 12.5. Market Trends
• 12.6. Key Market Participants - Intensity Mapping
• 12.7. Drivers and Restraints - Impact Analysis
• 12.8. Country Level Analysis & Forecast
  • 12.8.1. U.S. Vaginal Antifungals Market Analysis
    • 12.8.1.1. Introduction
    • 12.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 12.8.1.2.1. By Drug
      • 12.8.1.2.2. By Route of Administration
      • 12.8.1.2.3. By Distribution Channel
  • 12.8.2. Canada Vaginal Antifungals Market Analysis
    • 12.8.2.1. Introduction
    • 12.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 12.8.2.2.1. By Drug
      • 12.8.2.2.2. By Route of Administration
      • 12.8.2.2.3. By Distribution Channel

13. Latin America Vaginal Antifungals Market Analysis 2019-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 13.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 13.3.1. By Country
    • 13.3.1.1. Mexico
    • 13.3.1.2. Brazil
    • 13.3.1.3. Argentina
    • 13.3.1.4. Rest of Latin America
      • 13.3.1.4.1. By Country
      • 13.3.1.4.2. By Drug
      • 13.3.1.4.3. By Route of Administration
      • 13.3.1.4.4. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Drug
  • 13.4.3. By Route of Administration
  • 13.4.4. By Distribution Channel
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. Mexico Vaginal Antifungals Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.1.2.1. By Drug
      • 13.8.1.2.2. By Route of Administration
      • 13.8.1.2.3. By Distribution Channel
  • 13.8.2. Brazil Vaginal Antifungals Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.2.2.1. By Country
      • 13.8.2.2.2. By Drug
      • 13.8.2.2.3. By Route of Administration
      • 13.8.2.2.4. By Distribution Channel
  • 13.8.3. Argentina Vaginal Antifungals Market Analysis
    • 13.8.3.1. Introduction
    • 13.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 13.8.3.2.1. By Drug
      • 13.8.3.2.2. By Route of Administration
      • 13.8.3.2.3. By Distribution Channel

14. Europe Vaginal Antifungals Market Analysis 2019-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 14.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 14.3.1. By Country
    • 14.3.1.1. Germany
    • 14.3.1.2. Italy
    • 14.3.1.3. France
    • 14.3.1.4. U.K.
    • 14.3.1.5. Spain
    • 14.3.1.6. BENELUX
    • 14.3.1.7. Russia
    • 14.3.1.8. Rest of Europe
  • 14.3.2. By Drug
  • 14.3.3. By Route of Administration
  • 14.3.4. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug
  • 14.4.3. By Route of Administration
  • 14.4.4. By Distribution Channel
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Germany Vaginal Antifungals Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.1.2.1. By Drug
      • 14.8.1.2.2. By Route of Administration
      • 14.8.1.2.3. By Distribution Channel
  • 14.8.2. Italy Vaginal Antifungals Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.2.2.1. By Drug
      • 14.8.2.2.2. By Route of Administration
      • 14.8.2.2.3. By Distribution Channel
  • 14.8.3. France Vaginal Antifungals Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.3.2.1. By Drug
      • 14.8.3.2.2. By Route of Administration
      • 14.8.3.2.3. By Distribution Channel
  • 14.8.4. U.K. Vaginal Antifungals Market Analysis
    • 14.8.4.1. Introduction
    • 14.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.4.2.1. By Drug
      • 14.8.4.2.2. By Route of Administration
      • 14.8.4.2.3. By Distribution Channel
  • 14.8.5. Spain Vaginal Antifungals Market Analysis
    • 14.8.5.1. Introduction
    • 14.8.5.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.5.2.1. By Drug
      • 14.8.5.2.2. By Route of Administration
      • 14.8.5.2.3. By Distribution Channel
  • 14.8.6. BENELUX Vaginal Antifungals Market Analysis
    • 14.8.6.1. Introduction
    • 14.8.6.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.6.2.1. By Drug
      • 14.8.6.2.2. By Route of Administration
      • 14.8.6.2.3. By Distribution Channel
  • 14.8.7. Russia Vaginal Antifungals Market Analysis
    • 14.8.7.1. Introduction
    • 14.8.7.2. Market Analysis and Forecast By Market Taxonomy
      • 14.8.7.2.1. By Drug
      • 14.8.7.2.2. By Route of Administration
      • 14.8.7.2.3. By Distribution Channel

15. East Asia Vaginal Antifungals Market Analysis 2019-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 15.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 15.3.1. By Country
    • 15.3.1.1. China
    • 15.3.1.2. Japan
    • 15.3.1.3. South Korea
  • 15.3.2. By Drug
  • 15.3.3. By Route of Administration
  • 15.3.4. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug
  • 15.4.3. By Route of Administration
  • 15.4.4. By Distribution Channel
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. China Vaginal Antifungals Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.1.2.1. By Drug
      • 15.8.1.2.2. By Route of Administration
      • 15.8.1.2.3. By Distribution Channel
  • 15.8.2. Japan Vaginal Antifungals Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.2.2.1. By Drug
      • 15.8.2.2.2. By Route of Administration
      • 15.8.2.2.3. By Distribution Channel
  • 15.8.3. South Korea Vaginal Antifungals Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 15.8.3.2.1. By Drug
      • 15.8.3.2.2. By Route of Administration
      • 15.8.3.2.3. By Distribution Channel

16. South Asia Vaginal Antifungals Market Analysis 2019-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 16.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Indonesia
    • 16.3.1.3. Malaysia
    • 16.3.1.4. Thailand
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Drug
  • 16.3.3. By Route of Administration
  • 16.3.4. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Drug
  • 16.4.3. By Route of Administration
  • 16.4.4. By Distribution Channel
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. India Vaginal Antifungals Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.1.2.1. By Drug
      • 16.8.1.2.2. By Route of Administration
      • 16.8.1.2.3. By Distribution Channel
  • 16.8.2. Indonesia Vaginal Antifungals Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.2.2.1. By Drug
      • 16.8.2.2.2. By Route of Administration
      • 16.8.2.2.3. By Distribution Channel
  • 16.8.3. Malaysia Vaginal Antifungals Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.3.2.1. By Drug
      • 16.8.3.2.2. By Route of Administration
      • 16.8.3.2.3. By Distribution Channel
  • 16.8.4. Thailand Vaginal Antifungals Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 16.8.4.2.1. By Drug
      • 16.8.4.2.2. By Route of Administration
      • 16.8.4.2.3. By Distribution Channel

17. Oceania Vaginal Antifungals Market 2019-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 17.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 17.3.1. By Country
    • 17.3.1.1. Australia
    • 17.3.1.2. New Zealand
  • 17.3.2. By Drug
  • 17.3.3. By Route of Administration
  • 17.3.4. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug
  • 17.4.3. By Route of Administration
  • 17.4.4. By Distribution Channel
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Country Level Analysis & Forecast
  • 17.7.1. Australia Vaginal Antifungals Market Analysis
    • 17.7.1.1. Introduction
    • 17.7.1.2. Market Analysis and Forecast By Market Taxonomy
      • 17.7.1.2.1. By Drug
      • 17.7.1.2.2. By Route of Administration
      • 17.7.1.2.3. By Distribution Channel
  • 17.7.2. New Zealand Vaginal Antifungals Market Analysis
    • 17.7.2.1. Introduction
    • 17.7.2.2. Market Analysis and Forecast By Market Taxonomy
      • 17.7.2.2.1. By Drug
      • 17.7.2.2.2. By Route of Administration
      • 17.7.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Vaginal Antifungals Market Analysis 2019-2032

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2024
• 18.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2025-2032
  • 18.3.1. By Country
    • 18.3.1.1. GCC Countries
    • 18.3.1.2. Turkiye
    • 18.3.1.3. South Africa
    • 18.3.1.4. North Africa
    • 18.3.1.5. Rest of Middle East and Africa
  • 18.3.2. By Drug
  • 18.3.3. By Route of Administration
  • 18.3.4. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Drug
  • 18.4.3. By Route of Administration
  • 18.4.4. By Distribution Channel
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. GCC Countries Vaginal Antifungals Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.1.2.1. By Drug
      • 18.8.1.2.2. By Route of Administration
      • 18.8.1.2.3. By Distribution Channel
  • 18.8.2. Turkiye Vaginal Antifungals Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.2.2.1. By Drug
      • 18.8.2.2.2. By Route of Administration
      • 18.8.2.2.3. By Distribution Channel
  • 18.8.3. South Africa Vaginal Antifungals Market Analysis
    • 18.8.3.1. Introduction
    • 18.8.3.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.3.2.1. By Drug
      • 18.8.3.2.2. By Route of Administration
      • 18.8.3.2.3. By Distribution Channel
  • 18.8.4. North Africa Vaginal Antifungals Market Analysis
    • 18.8.4.1. Introduction
    • 18.8.4.2. Market Analysis and Forecast By Market Taxonomy
      • 18.8.4.2.1. By Drug
      • 18.8.4.2.2. By Route of Administration
      • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

• 19.1. Market Analysis By Tier of Companies
• 19.2. Market Concentration
• 19.3. Market Share Analysis of Top Players
• 19.4. Market Presence Analysis

20. Competition Analysis

• 20.1. Competition Dashboard
• 20.2. Competition Benchmarking
• 20.3. Competition Deep Dive
  • 20.3.1. Pfizer Inc.
    • 20.3.1.1. Overview
    • 20.3.1.2. Product Portfolio
    • 20.3.1.3. Sales Footprint
    • 20.3.1.4. Key Financials
    • 20.3.1.5. SWOT Analysis
    • 20.3.1.6. Strategic Overview
  • 20.3.2. Bausch Health Companies Inc
    • 20.3.2.1. Overview
    • 20.3.2.2. Product Portfolio
    • 20.3.2.3. Sales Footprint
    • 20.3.2.4. Key Financials
    • 20.3.2.5. SWOT Analysis
    • 20.3.2.6. Strategic Overview
  • 20.3.3. ANI Pharmaceuticals, Inc.
    • 20.3.3.1. Overview
    • 20.3.3.2. Product Portfolio
    • 20.3.3.3. Sales Footprint
    • 20.3.3.4. Key Financials
    • 20.3.3.5. SWOT Analysis
    • 20.3.3.6. Strategic Overview
  • 20.3.4. Hikma Pharmaceuticals Plc
    • 20.3.4.1. Overview
    • 20.3.4.2. Product Portfolio
    • 20.3.4.3. Sales Footprint
    • 20.3.4.4. Key Financials
    • 20.3.4.5. SWOT Analysis
    • 20.3.4.6. Strategic Overview
  • 20.3.5. Lupin Limited
    • 20.3.5.1. Overview
    • 20.3.5.2. Product Portfolio
    • 20.3.5.3. Sales Footprint
    • 20.3.5.4. Key Financials
    • 20.3.5.5. SWOT Analysis
    • 20.3.5.6. Strategic Overview
  • 20.3.6. Mycovia Pharmaceuticals, Inc.
    • 20.3.6.1. Overview
    • 20.3.6.2. Product Portfolio
    • 20.3.6.3. Sales Footprint
    • 20.3.6.4. Key Financials
    • 20.3.6.5. SWOT Analysis
    • 20.3.6.6. Strategic Overview
  • 20.3.7. Glenmark Pharmaceuticals Limited
    • 20.3.7.1. Overview
    • 20.3.7.2. Product Portfolio
    • 20.3.7.3. Sales Footprint
    • 20.3.7.4. Key Financials
    • 20.3.7.5. SWOT Analysis
    • 20.3.7.6. Strategic Overview
  • 20.3.8. Unique Pharmaceuticals
    • 20.3.8.1. Overview
    • 20.3.8.2. Product Portfolio
    • 20.3.8.3. Sales Footprint
    • 20.3.8.4. Key Financials
    • 20.3.8.5. SWOT Analysis
    • 20.3.8.6. Strategic Overview
  • 20.3.9. PEPTONIC medical AB
    • 20.3.9.1. Overview
    • 20.3.9.2. Product Portfolio
    • 20.3.9.3. Sales Footprint
    • 20.3.9.4. Key Financials
    • 20.3.9.5. SWOT Analysis
    • 20.3.9.6. Strategic Overview
  • 20.3.10. Aurobindo Pharma Limited
    • 20.3.10.1. Overview
    • 20.3.10.2. Product Portfolio
    • 20.3.10.3. Sales Footprint
    • 20.3.10.4. Key Financials
    • 20.3.10.5. SWOT Analysis
    • 20.3.10.6. Strategic Overview
  • 20.3.11. Dr. Reddy's Laboratories
    • 20.3.11.1. Overview
    • 20.3.11.2. Product Portfolio
    • 20.3.11.3. Sales Footprint
    • 20.3.11.4. Key Financials
    • 20.3.11.5. SWOT Analysis
    • 20.3.11.6. Strategic Overview
  • 20.3.12. SCYNEXIS, Inc.
    • 20.3.12.1. Overview
    • 20.3.12.2. Product Portfolio
    • 20.3.12.3. Sales Footprint
    • 20.3.12.4. Key Financials
    • 20.3.12.5. SWOT Analysis
    • 20.3.12.6. Strategic Overview
  • 20.3.13. Basilea Pharmaceutica Ltd.
    • 20.3.13.1. Overview
    • 20.3.13.2. Product Portfolio
    • 20.3.13.3. Sales Footprint
    • 20.3.13.4. Key Financials
    • 20.3.13.5. SWOT Analysis
    • 20.3.13.6. Strategic Overview
  • 20.3.14. Astellas Pharma Inc.
    • 20.3.14.1. Overview
    • 20.3.14.2. Product Portfolio
    • 20.3.14.3. Sales Footprint
    • 20.3.14.4. Key Financials
    • 20.3.14.5. SWOT Analysis
    • 20.3.14.6. Strategic Overview
  • 20.3.15. Grupo Ferrer Internacional, S.A.
    • 20.3.15.1. Overview
    • 20.3.15.2. Product Portfolio
    • 20.3.15.3. Sales Footprint
    • 20.3.15.4. Key Financials
    • 20.3.15.5. SWOT Analysis
    • 20.3.15.6. Strategic Overview
  • 20.3.16. Pacgen Life Science Corporation
    • 20.3.16.1. Overview
    • 20.3.16.2. Product Portfolio
    • 20.3.16.3. Sales Footprint
    • 20.3.16.4. Key Financials
    • 20.3.16.5. SWOT Analysis
    • 20.3.16.6. Strategic Overview
  • 20.3.17. NovaDigm Therapeutics, Inc.
    • 20.3.17.1. Overview
    • 20.3.17.2. Product Portfolio
    • 20.3.17.3. Sales Footprint
    • 20.3.17.4. Key Financials
    • 20.3.17.5. SWOT Analysis
    • 20.3.17.6. Strategic Overview
  • 20.3.18. Cidara Therapeutics, Inc.
    • 20.3.18.1. Overview
    • 20.3.18.2. Product Portfolio
    • 20.3.18.3. Sales Footprint
    • 20.3.18.4. Key Financials
    • 20.3.18.5. SWOT Analysis
    • 20.3.18.6. Strategic Overview
  • 20.3.19. Amplyx Pharmaceuticals Inc.
    • 20.3.19.1. Overview
    • 20.3.19.2. Product Portfolio
    • 20.3.19.3. Sales Footprint
    • 20.3.19.4. Key Financials
    • 20.3.19.5. SWOT Analysis
    • 20.3.19.6. Strategic Overview

21. Assumptions and Acronyms Used

22. Research Methodology